These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 24737346)
41. PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients. Beelen K; Opdam M; Severson TM; Koornstra RH; Vincent AD; Wesseling J; Muris JJ; Berns EM; Vermorken JB; van Diest PJ; Linn SC Breast Cancer Res; 2014 Jan; 16(1):R13. PubMed ID: 24467828 [TBL] [Abstract][Full Text] [Related]
42. MicroRNAs and the PTEN/PI3K/Akt pathway in gastric cancer (Review). Hu M; Zhu S; Xiong S; Xue X; Zhou X Oncol Rep; 2019 Mar; 41(3):1439-1454. PubMed ID: 30628706 [TBL] [Abstract][Full Text] [Related]
43. Akt-p53-miR-365-cyclin D1/cdc25A axis contributes to gastric tumorigenesis induced by PTEN deficiency. Guo SL; Ye H; Teng Y; Wang YL; Yang G; Li XB; Zhang C; Yang X; Yang ZZ; Yang X Nat Commun; 2013; 4():2544. PubMed ID: 24149576 [TBL] [Abstract][Full Text] [Related]
44. Genetic variation in AKT1, PTEN and the 8q24 locus, and the risk of testicular germ cell tumor. Andreassen KE; Kristiansen W; Karlsson R; Aschim EL; Dahl O; Fosså SD; Adami HO; Wiklund F; Haugen TB; Grotmol T Hum Reprod; 2013 Jul; 28(7):1995-2002. PubMed ID: 23639623 [TBL] [Abstract][Full Text] [Related]
45. Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway. Rubinstein MM; Hyman DM; Caird I; Won H; Soldan K; Seier K; Iasonos A; Tew WP; O'Cearbhaill RE; Grisham RN; Hensley ML; Troso-Sandoval T; Sabbatini P; Guillen J; Selcuklu SD; Zimel C; Torrisi J; Aghajanian C; Makker V Cancer; 2020 Mar; 126(6):1274-1282. PubMed ID: 31880826 [TBL] [Abstract][Full Text] [Related]
46. Single Nucleotide Polymorphism of the Enhancer of Zeste Homolog 2 Gene rs2072408 is Associated with Lymph Node Metastasis and Depth of Primary Tumor Invasion in Gastric Cancer. Sun B; Lin Y; Wang X; Lan F; Yu Y; Huang Q Clin Lab; 2016 Nov; 62(11):2099-2105. PubMed ID: 28164661 [TBL] [Abstract][Full Text] [Related]
47. Alterations in the human epidermal growth factor receptor 2-phosphatidylinositol 3-kinase-v-Akt pathway in gastric cancer. Sukawa Y; Yamamoto H; Nosho K; Kunimoto H; Suzuki H; Adachi Y; Nakazawa M; Nobuoka T; Kawayama M; Mikami M; Matsuno T; Hasegawa T; Hirata K; Imai K; Shinomura Y World J Gastroenterol; 2012 Dec; 18(45):6577-86. PubMed ID: 23236232 [TBL] [Abstract][Full Text] [Related]
48. Diet and colorectal cancer: analysis of a candidate pathway using SNPS, haplotypes, and multi-gene assessment. Slattery ML; Lundgreen A; Herrick JS; Caan BJ; Potter JD; Wolff RK Nutr Cancer; 2011 Nov; 63(8):1226-34. PubMed ID: 21999454 [TBL] [Abstract][Full Text] [Related]
49. Inhibitory effects of adenovirus mediated Akt1 and PIK3R1 shRNA on the growth of malignant tumor cells in vitro and in vivo. Fu Y; Zhang Q; Kang C; Zhang J; Zhang K; Pu P; Wang G; Wang T Cancer Biol Ther; 2009 Jun; 8(11):1002-9. PubMed ID: 19305146 [TBL] [Abstract][Full Text] [Related]
50. Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene mutations. Lee JB; Jung M; Beom SH; Kim GM; Kim HR; Choi HJ; Sohn JH; Ahn JB; Rha SY; Chung HC Invest New Drugs; 2021 Oct; 39(5):1366-1374. PubMed ID: 33723724 [TBL] [Abstract][Full Text] [Related]
51. [Construction of recombinant adenovirus vector expressing shRNAs targeting COX-2, AKT1 and PIK3R1 gene and its inhibition effect on proliferation of human gastric adenocarcinoma]. Fu YC; Zhang J; Zhang KR; Zhang QY; Kang CS; Wang T Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2009 Aug; 26(4):383-7. PubMed ID: 20017300 [TBL] [Abstract][Full Text] [Related]
52. The AKT1/NF-kappaB/Notch1/PTEN axis has an important role in chemoresistance of gastric cancer cells. Zhou W; Fu XQ; Zhang LL; Zhang J; Huang X; Lu XH; Shen L; Liu BN; Liu J; Luo HS; Yu JP; Yu HG Cell Death Dis; 2013 Oct; 4(10):e847. PubMed ID: 24113181 [TBL] [Abstract][Full Text] [Related]
53. Germline PIK3CA and AKT1 mutations in Cowden and Cowden-like syndromes. Orloff MS; He X; Peterson C; Chen F; Chen JL; Mester JL; Eng C Am J Hum Genet; 2013 Jan; 92(1):76-80. PubMed ID: 23246288 [TBL] [Abstract][Full Text] [Related]
54. Mutational and immunohistochemical study of the PI3K/Akt pathway in papillary thyroid carcinoma in Greece. Sozopoulos E; Litsiou H; Voutsinas G; Mitsiades N; Anagnostakis N; Tseva T; Patsouris E; Tseleni-Balafouta S Endocr Pathol; 2010 Jun; 21(2):90-100. PubMed ID: 20186503 [TBL] [Abstract][Full Text] [Related]
55. Mutation of genes of the PI3K/AKT pathway in breast cancer supports their potential importance as biomarker for breast cancer aggressiveness. Tserga A; Chatziandreou I; Michalopoulos NV; Patsouris E; Saetta AA Virchows Arch; 2016 Jul; 469(1):35-43. PubMed ID: 27059323 [TBL] [Abstract][Full Text] [Related]
56. PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Esteva FJ; Guo H; Zhang S; Santa-Maria C; Stone S; Lanchbury JS; Sahin AA; Hortobagyi GN; Yu D Am J Pathol; 2010 Oct; 177(4):1647-56. PubMed ID: 20813970 [TBL] [Abstract][Full Text] [Related]
57. MicroRNA-106b promotes pituitary tumor cell proliferation and invasion through PI3K/AKT signaling pathway by targeting PTEN. Zhou K; Zhang T; Fan Y; Serick ; Du G; Wu P; Geng D Tumour Biol; 2016 Oct; 37(10):13469-13477. PubMed ID: 27465551 [TBL] [Abstract][Full Text] [Related]
58. Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict head and neck cancer patient second primary tumor/recurrence risk and response to retinoid chemoprevention. Hildebrandt MA; Lippman SM; Etzel CJ; Kim E; Lee JJ; Khuri FR; Spitz MR; Lotan R; Hong WK; Wu X Clin Cancer Res; 2012 Jul; 18(13):3705-13. PubMed ID: 22577058 [TBL] [Abstract][Full Text] [Related]
59. PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer. Sood A; McClain D; Maitra R; Basu-Mallick A; Seetharam R; Kaubisch A; Rajdev L; Mariadason JM; Tanaka K; Goel S Clin Colorectal Cancer; 2012 Jun; 11(2):143-50. PubMed ID: 22285706 [TBL] [Abstract][Full Text] [Related]
60. Analysis of PIK3CA Mutations and Activation Pathways in Triple Negative Breast Cancer. Cossu-Rocca P; Orrù S; Muroni MR; Sanges F; Sotgiu G; Ena S; Pira G; Murgia L; Manca A; Uras MG; Sarobba MG; Urru S; De Miglio MR PLoS One; 2015; 10(11):e0141763. PubMed ID: 26540293 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]